Loading publications…
The last 5 uploaded publications
DNA methylation-based reclassification of olfactory neuroblastoma
David Capper, Nils W. Engel, Damian Stichel, Matt Lechner, Stefanie Glöß, Simone Schmid, Christian Koelsche, Daniel Schrimpf, Judith Niesen, Annika K. Wefers, David Jones, Martin Sill, Oliver Weigert, Keith L. Ligon, Adriana Olar, Arend Koch, Martin Förster, Sebastián Morán, Òscar M. Tirado, Miguel Sáinz‐Jaspeado, Jaume Mora, Manel Esteller, Javier Alonso, Xavier García del Muro, Werner Paulus, Jörg Felsberg, Guido Reifenberger, Markus Glatzel, Stephan Frank, Camelia M. Monoranu, Valerie J. Lund, Andreas von Deimling, Stefan M. Pfister, Rolf Buslei, Julika Ribbat‐Idel, Sven Perner, Volker Gudziol, Matthias Meinhardt, Ulrich Schüller (2018). DNA methylation-based reclassification of olfactory neuroblastoma. , 136(2), DOI: https://doi.org/10.1007/s00401-018-1854-7.
Article74 days agoThe poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen Sandhu, William R. Schelman, George Wilding, Víctor Moreno, Richard D. Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Förster, Aurelius Omlin, N. Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John W. Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L. Carpenter, Robert Iannone, Stan B. Kaye, Johann S. de Bono, Robert M. Wenham (2013). The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. , 14(9), DOI: https://doi.org/10.1016/s1470-2045(13)70240-7.
Article62 days agoTreatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Martin Förster, Konstantin J. Dedes, Shahneen Sandhu, Sophia Frentzas, Rebecca Kristeleit, Alan Ashworth, Christopher Poole, Britta Weigelt, Stan B. Kaye, L Rhoda Molife (2011). Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. , 8(5), DOI: https://doi.org/10.1038/nrclinonc.2011.42.
Article62 days agoPre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.
Martin Förster, Amita Patnaik, Shahneen Sandhu, K. Papadopoulos, Brenda Tromp, Christina Messiou, Frances R. Balkwill, Birge Berns, Johann S. de Bono, A. W. Tolcher (2010). Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.. , 28(15_suppl), DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.2548.
Article62 days agoTreatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Martin Förster, Konstantin J. Dedes, Shahneen Sandhu, Sophia Frentzas, Rebecca Kristeleit, Alan Ashworth, Christopher Poole, Britta Weigelt, Stan B. Kaye, L Rhoda Molife (2011). Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. , 8(5), DOI: https://doi.org/10.1038/nrclinonc.2011.42.
Article62 days ago